The Effect of PPI Therapy on the Result of Helicobacter Pylori Diagnostic Tests
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01278901|
Recruitment Status : Unknown
Verified January 2011 by Rabin Medical Center.
Recruitment status was: Not yet recruiting
First Posted : January 19, 2011
Last Update Posted : January 19, 2011
The study will include 30 patients ages 18-80y that had a gastroscopy for various reasons. The patients should not be on PPI therapy . If during the gastroscopy there are some pathologies that require a second look endoscopy after some weeks of therapy (ulcers or esophagitis), the investigators will repeat the gastroscopy within a month.
During the first gastroscopy a biopsy will be taken for histological examination and for a rapid urease test and an urea breath test will be done soon after the procedure.
If one of the tests is positive the investigators postulate that the Helicobacter pylori is actually present.
After the gastroscopy the patient is given a full dose of PPI (as indicated) and helicobacter tests are repeated in the next endoscopy (under PPI therapy) . Any positive test that become negative in the second endoscopy is considered false negative.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Study Start Date :||February 2011|
|Estimated Primary Completion Date :||February 2012|
Cohort of consecutive patients undergoing EGD treated with PPI
Patients positive for helicobacter pylori undergoing EGD, started on PPI therapy for a month, repeated diagnostic tests for Helicobacter pylori after a month of therapy (urease test, histology and breath test)
- Effect of PPI treatment on helicobacter pylori diagnostic tests [ Time Frame: 1 month of therapy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01278901
|Contact: Vered Shabat, MD||972-3-9732798 ext firstname.lastname@example.org|
|Department of Gastroenterology, Rabin Medical Center||Not yet recruiting|
|Petach Tikva, Israel, 49100|
|Contact: Vered Shabat, MD 972-3-9732798 ext 2798 email@example.com|